Javier E. Oesterheld

Javier E. Oesterheld

Hematology | Oncology

1000 Blythe Blvd.
Charlotte, NC 28203

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 21 publications

In Vitro and In Vivo Efficacy of Romidepsin Alone and in Addition to Standard of Care for Treatment of Ewing Sarcoma.

In Vitro and In Vivo Efficacy of Romidepsin Alone and in Addition to Standard of Care for Treatment of Ewing Sarcoma.

Journal: Cancers

Published: November 12, 2025

Mitoxantrone in combination with clofarabine (MITCL) in children, adolescents and young adults with relapsed/refractory acute leukaemia: final results of a phase I/II trial.

Mitoxantrone in combination with clofarabine (MITCL) in children, adolescents and young adults with relapsed/refractory acute leukaemia: final results of a phase I/II trial.

Journal: EClinicalMedicine

Published: February 04, 2025

Panobinostat Synergizes with Chemotherapeutic Agents and Improves Efficacy of Standard-of-Care Chemotherapy Combinations in Ewing Sarcoma Cells.

Panobinostat Synergizes with Chemotherapeutic Agents and Improves Efficacy of Standard-of-Care Chemotherapy Combinations in Ewing Sarcoma Cells.

Journal: Cancers

Published: September 23, 2024

Naxitamab-combination Therapy for the Treatment of Patients With Refractory and/or Relapsed High-risk Neuroblastoma.

Naxitamab-combination Therapy for the Treatment of Patients With Refractory and/or Relapsed High-risk Neuroblastoma.

Journal: Journal of pediatric hematology/oncology

Published: September 23, 2024

Phase II Trial of Gemcitabine and Nab-Paclitaxel for Recurrent Osteosarcoma with Serial Monitoring Using Liquid Biopsy: A Report from the National Pediatric Cancer Foundation.

Phase II Trial of Gemcitabine and Nab-Paclitaxel for Recurrent Osteosarcoma with Serial Monitoring Using Liquid Biopsy: A Report from the National Pediatric Cancer Foundation.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: April 27, 2024

Eflornithine as Postimmunotherapy Maintenance in High-Risk Neuroblastoma: Externally Controlled, Propensity Score-Matched Survival Outcome Comparisons.

Eflornithine as Postimmunotherapy Maintenance in High-Risk Neuroblastoma: Externally Controlled, Propensity Score-Matched Survival Outcome Comparisons.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: October 26, 2023

Guidelines for outpatient administration of naxitamab: Experience from Atrium Health Levine Children's Hospital.

Guidelines for outpatient administration of naxitamab: Experience from Atrium Health Levine Children's Hospital.

Journal: Cancer medicine

Published: August 25, 2023

Molecular-guided therapy for the treatment of patients with relapsed and refractory childhood cancers: a Beat Childhood Cancer Research Consortium trial.

Molecular-guided therapy for the treatment of patients with relapsed and refractory childhood cancers: a Beat Childhood Cancer Research Consortium trial.

Journal: Genome medicine

Published: August 17, 2023

ALK rearrangements in infantile fibrosarcoma-like spindle cell tumours of soft tissue and kidney.

ALK rearrangements in infantile fibrosarcoma-like spindle cell tumours of soft tissue and kidney.

Journal: Histopathology

Published: October 04, 2021

A pilot study of genomic-guided induction therapy followed by immunotherapy with difluoromethylornithine maintenance for high-risk neuroblastoma.

A pilot study of genomic-guided induction therapy followed by immunotherapy with difluoromethylornithine maintenance for high-risk neuroblastoma.

Journal: Cancer reports (Hoboken, N.J.)

Published: September 10, 2021

Genomic and Transcriptomic Analysis of Relapsed and Refractory Childhood Solid Tumors Reveals a Diverse Molecular Landscape and Mechanisms of Immune Evasion.

Genomic and Transcriptomic Analysis of Relapsed and Refractory Childhood Solid Tumors Reveals a Diverse Molecular Landscape and Mechanisms of Immune Evasion.

Journal: Cancer research

Published: April 02, 2021

A dose substitution of anthracycline intensity with dose-dense rituximab in children and adolescents with good-risk mature B-cell lymphoma.

A dose substitution of anthracycline intensity with dose-dense rituximab in children and adolescents with good-risk mature B-cell lymphoma.

Journal: Leukemia

Published: September 03, 2020

Showing 1-12 of 21

Last Updated: 09/26/2026